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Over the past 50 years, a trend has been 
reported toward earlier pubertal develop-
ment in girls, with the implication that early 
maturation may lead to adverse social and 
medical conditions, including cancer and 
diabetes (Schoeters et al. 2008). Race, obe-
sity, and genetics are likely determinants of 
pubertal timing, but hormonally active 
environmental exposures may also play 
a role (Jacobson-Dickman and Lee 2009). 
Widespread exposure exists to such envi-
ronmental agents. Children and minorities 
often have higher exposures, as demonstrated 
by urinary concentrations of many environ-
mental biomarkers, compared with adults 
and whites [Centers for Disease Control and 
Prevention (CDC) 2005]. Specific chemicals 
that behave like estradiol include a number 
of phenols, such as bisphenol A. They act as 
hormone agonists in animal models of repro-
ductive development, accelerating pubertal 
development. However, phytoestrogens and 
phthalates have both agonist and antagonist 
effects in animals, likely related to alternative 
mechanisms, dose levels, and exposure timing 
(Rasier et al. 2006).
The Breast Cancer and Environment 
Research Centers (BCERC) are a consor-
tium established by the National Institute 
of Environmental Health Sciences and The 
National Cancer Institute to elucidate influ-
ences of environmental factors on timing of 
pubertal development in girls. For this pur-
pose, we evaluated exposure using concur-
rent urinary biomarkers representing three 
classes of environmental agents in relation to 
breast and pubic hair development among the 
girls in this cohort. Biomarkers were selected 
based on a pilot study that revealed a wide 
range of values and high detectability in our 
cohort (Wolff et al. 2007). We hypothesized 
that phenols would be associated with earlier 
puberty, that phthalate biomarkers would be 
related to later pubertal timing, that phytoe-
strogens would be associated with later breast 
development, and that associations could be 
modified by obesity.
Materials and Methods
Study population. The BCERC epidemiology 
project is a longitudinal study of girls enrolled 
at 6–8 years of age and followed through 
puberty. It is part of a consortium of four cen-
ters with transdisciplinary research collabora-
tions integrated across biologic, epidemiologic, 
and community outreach projects. Enrollment 
of 1,239 girls during 2004–2007 occurred at 
three sites: Mount Sinai School of Medicine 
(MSSM), which recruited in East Harlem 
in New York City; Cincinnati Children’s 
Hospital (Cincinnati), which recruited in the 
greater Cincinnati, Ohio, metropolitan area, 
and through the Breast Cancer Registry of 
Greater Cincinnati; and Kaiser Permanente 
Northern California (KPNC), which recruited 
members of the KPNC Health Plan in the 
San Francisco Bay Area. All sites obtained 
informed consent from parent or guard-
ian and independently verified child assent, 
approved by the institutional review boards at 
each institution and at the CDC. Eligibility 
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Ba c k g r o u n d: Hormonally active environmental agents may alter the course of pubertal   development 
in girls, which is controlled by steroids and gonadotropins.
oBjectives: We investigated associations of concurrent exposures from three chemical classes 
(  phenols, phthalates, and phytoestrogens) with pubertal stages in a multiethnic longitudinal study of 
1,151 girls from New York City, New York, greater Cincinnati, Ohio, and northern California who 
were 6–8 years of age at enrollment (2004–2007).
Me t h o d s : We measured urinary exposure biomarkers at visit 1 and examined associations with 
breast and pubic hair development (present or absent, assessed 1 year later) using multivariate 
adjusted prevalence ratios (PR) and 95% confidence intervals (CIs). Modification of biomarker 
associations by age-specific body mass index percentile (BMI%) was investigated, because adipose 
tissue is a source of peripubertal hormones.
re s u l t s: Breast development was present in 30% of girls, and 22% had pubic hair. High-molecular-
weight phthalate (high MWP) metabolites were weakly associated with pubic hair development 
[adjusted PR, 0.94 (95% CI, 0.88–1.00), fifth vs. first quintile]. Small inverse associations were seen 
for daidzein with breast stage and for triclosan and high MWP with pubic hair stage; a positive trend 
was observed for low-molecular-weight phthalate biomarkers with breast and pubic hair develop-
ment. Enterolactone attenuated BMI associations with breast development. In the first enterolac-
tone quintile, for the association of high BMI with any development, the PR was 1.34 (95% CI, 
1.23–1.45 vs. low BMI). There was no BMI association in the fifth, highest quintile of enterolactone.
co n c l u s i o n s: Weak hormonally active xenobiotic agents investigated in this study had small asso-
ciations with pubertal development, mainly among those agents detected at highest concentrations.
key w o r d s : biomarkers, phenols, phthalates, phytoestrogens, puberty. Environ Health Perspect 
118:1039–1046 (2010).  doi:10.1289/ehp.0901690 [Online 22 March 2010]Wolff et al.
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included age, female sex, no underlying endo-
crine medical conditions, and at MSSM, black 
or Hispanic race/ethnicity.
Data collection. A questionnaire was com-
pleted by the parent or guardian of the girl 
(usually the mother) that included medical 
history, product use and exposures, and demo-
graphic variables. Parents or guardians identi-
fied the girls as black, white, Asian, or other, 
and ethnicity as Hispanic or non-Hispanic. 
We assessed age, weight, height, breast and 
pubic hair stages at the visit when urine was 
collected (visit 1) and approximately 1 year 
later (visit 2). Visits 1 for MSSM and KPNC 
were at baseline. Visit 1 for Cincinnati is 
defined for this analysis as the visit when urine 
was collected, which was 6 months after the 
first baseline visit. Visit 2 was approximately 
1 year later [details in Supplemental Material, 
Table 1 (doi:10.1289/ehp.0901690)]. At 
each visit, breast (B1–B5) and pubic hair 
(PH1–PH5) stages were assessed by inspec-
tion and palpation. Examiners were trained 
and tested by a master clinician, following a 
written protocol with photographs that dem-
onstrated the maturation stages (Biro et al., in 
press; van Wieringen et al. 1985). Inter-rater 
evaluations were conducted by one pediatri-
cian. The kappa statistic was 0.67, indicating 
substantial agreement; concordance was 87% 
(117/127 among 39 examiners) (Biro et al., 
in press). Height and weight were measured 
using calibrated scales and stadiometers at 
each visit. Age-specific (in months) and sex-
specific body mass index percentiles (BMI%) 
were calculated based on CDC growth charts 
(CDC 2000). Pubertal stages and BMI% dis-
tribution at visit 1 were similar among girls 
with visit 2 breast stages (n = 985) and with-
out (n = 166) visit 2 data; however, girls with-
out visit 2 data were more likely to be black 
or Hispanic, of lower socioeconomic status, 
and from MSSM (Table 1).
Urinary biomarker measurements. 
Samples collected at visit 1 were analyzed 
at the National Center for Environmental 
Health laboratories at CDC for nine phtha-
late metabolites [n = 1,149; monoethyl-
phthalate (MEP), mono-butyl phthalate, 
mono-iso-butyl phthalate, mono-benzyl 
phthalate, mono-3-carboxypropyl phthalate, 
mono-2-ethyl-5-carboxypentyl phthalate, 
mono-(2-ethyl-5-hydroxylhexyl) phthalate, 
mono-(2-ethyl-5-oxohexyl) phthalate, and 
mono-(2-ethylhexyl) phthalate (MEHP)], 
seven phenols (benzophenone-3, bisphenol A, 
2,5-dichlorophenol, triclosan; n = 1,149; 
methyl-, butyl-, and propyl- parabens, n = 
1,059), and three phytoestrogens (daidzein, 
genistein, enterolactone; n = 1,150). Parabens 
were not measured early in the study. At least 
one urinary biomarker measurement was avail-
able among 1,151 girls, 985 with breast stages. 
We substituted limit of detection (LOD)/√
–– 2 
for results below the LOD. Adjustment for 
urine dilution was accomplished using crea-
tinine, to account for difference in sampling 
(spot specimens at MSSM and KPNC, early-
morning samples at Cincinnati) and interindi-
vidual variation in urine dilution. We included 
log-creatinine in models using continu-
ous log-biomarker variables, and we created 
quintile cut points from creatinine-corrected 
concentrations (micrograms per gram creati-
nine). As previously described, to reduce mul-
tiple comparisons we combined the phthalate 
metabolites into two groups that represent sim-
ilar sources and similar biologic activity, low- 
(< 250 Da) and high-molecular-weight (> 250 
Da) phthalate metabolites (low MWP and 
high MWP) [details in Supplemental Material, 
Table 2 (doi:10.1289/ehp.0901690)]. We 
expressed high MWP molar sum as MEHP 
(molecular weight 278) and the low MWP 
as MEP (molecular weight 194) so that units 
were the same as the other analytes (micro-
grams per liter). Similarly, a molar sum of the 
paraben metabolites was created (paraben sum) 
expressed as propyl paraben (molecular weight 
180.2). Models with the individual phthalate 
and paraben metabolites were consistent with 
the molar sum variables. Results using di(2-
ethylhexyl)phthalate (DEHP)-sum metabo-
lites were almost identical to those for the 
Table 1. Characteristics at visit 1 and by site for 1,151 girls with at least one biomarker value: BCERC 
cohort, 2004–2007 [n (%)].
Variable All sites combined MSSM Cincinnati KPNC
Age at baseline (visit 1) (years)
6.0–6.9 293 (25.5) 153 (37.7) 71 (22.0) 69 (16.4)
7.0–7.9 571 (49.6) 131 (32.3) 148 (45.8) 292 (69.2)
≥ 8.0–9.4 287 (24.9) 122 (30.0) 104 (32.2) 61 (14.5)
Median age 7.50 7.25 7.64 7.41
Age at visit 2 (years)
6.9–7.9 245 (21.3) 105 (25.9) 65 (20.2) 75 (17.8)
8.0–8.9 478 (41.5) 97 (23.9) 133 (14.3) 247 (58.7)
≥ 9.0–10.6 266 (23.1) 103 (25.4) 92 (28.6) 70 (16.6)
Not seen including missing (1) 162 101 32 29
Median age 8.50 8.41 8.66 8.50
Child race/ethnicity
White 391 (34.0) 0 (0.0) 220 (68.1) 171 (40.5)
Black 353 (30.7) 164 (40.4) 97 (30.0) 92 (21.8)
Hispanic, non-black 344 (29.9) 242 (59.6) 1 (0.3) 101 (23.9)
Asian 53 (4.6) 0 (0.0) 4 (1.2) 49 (11.6)
Other 10 (0.9) 0 (0.0) 1 (0.3) 9 (2.1)
BMI age- and sex-specific percentile
< 50th 394 (34.2) 133 (32.8) 101 (31.3) 160 (37.9)
 50–85th 388 (33.7) 114 (28.1) 132 (40.9) 142 (33.6)
≥ 85th 369 (32.1) 159 (39.2) 90 (27.9) 120 (28.4)
Parent or guardian education
≤ High school 342 (29.7) 236 (58.1) 29 (9.0) 77 (18.2)
> High school 765 (66.5) 162 (39.9) 261 (80.8) 342 (81.0)
Missing 44 8 33 3
Season of urine collection
Spring (March–May) 393 (34.1) 112 (27.6) 163 (50.5) 118 (28.0)
Summer (June–August) 322 (28.0) 94 (23.2) 48 (14.9) 71 (16.8)
Fall (September–November) 213 (18.5) 90 (22.2) 64 (19.8) 168 (39.8)
Winter (December–February) 223 (19.4) 110 (27.1) 48 (14.9) 65 (15.4)
Interval between visits 1 and 2
< 14 months 893 (90.5) 239 (78.4) 288 (99.0) 367 (93.6)
≥ 14 months 94 (9.5) 66 (21.6) 3 (1.0) 25 (6.4)
Breast stage at visit 1
B1 943 (81.9) 317 (78.1) 237 (73.4) 389 (92.2)
B2+ 206 (17.9) 89 (21.9) 86 (26.6) 31 (7.4)
Missing 2 0 0 2
Breast stage at visit 2
B1 688 (59.8) 194 (47.8) 167 (51.7) 327 (77.5)
B2+ 297 (25.8) 111 (27.3) 124 (38.4) 62 (14.7)
Not seen including missing (5) 166 101 32 33
Pubic hair stage at visit 1
PH1 979 (85.1) 334 (82.3) 275 (85.1) 370 (87.7)
PH2+ 151 (13.1) 71 (17.5) 43 (13.3) 37 (8.8)
Missing 21 1 5 15
Pubic hair stage at visit 2
PH1 756 (65.7) 216 (53.2) 230 (71.2) 310 (73.5)
PH2+ 211 (18.3) 88 (21.7) 61 (18.9) 62 (14.7)
Not seen including missing (23) 184 102 32 50
Total n 1,151 406 323 422Concurrent environmental exposures and puberty in girls
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high MWP, and they represented 75% ± 16% 
(mean ± SD) of the high MWP biomarkers. 
Therefore, only the latter models are presented.
Laboratory techniques and quality con-
trol protocols are identical to those reported 
previously in a pilot study (Wolff et al. 2007). 
Briefly, urine undergoes an automated cleanup 
with enzymatic deconjugation, followed by 
high-performance liquid chromatography-
isotope dilution tandem mass spectrometry 
quantification (Kato et al. 2005; Rybak et al. 
2008; Ye et al. 2005, 2006). In addition to 
the internal CDC quality control procedures, 
we incorporated approximately 10% masked 
quality control specimens (n = 101) from a 
single urine pool. The coefficients of variation 
(SD/mean concentration) were < 10% for 13 
analytes and were between 10% and 21% for 
the remaining six biomarkers.
Statistical analyses. We examined relation-
ships among pubertal stages, biomarkers, and 
study characteristics using nonparametric statis-
tics (Spearman or Kruskal–Wallis) and multi-
variate linear regression (version 9.1.3; SAS 
Institute Inc., Cary, NC). We conducted multi-
variate analyses using Proc Genmod (SAS) with 
modified Poisson regression, which provides 
robust error variance estimates and is appropri-
ate for outcomes that are not rare (Zou 2004). 
We computed prevalence ratios (PRs) and 95% 
confidence intervals (CIs) for any development 
[breast stage 2 or higher (B2+); pubic hair 
stage 2 or higher (PH2+)] versus no develop-
ment (B1 or PH1) in relation to biomarker 
exposures. We considered covariates related to 
pubertal development and urinary biomarker 
concentrations. Variables that did not alter any 
biomarker estimate by > 10% were backward-
eliminated from the models. Excluding obser-
vations with very dilute biospecimens (n = 58 
with creatinine < 0.2 g/L) did not materially 
change biomarker estimates; therefore, they 
were retained in the analyses. We assessed the 
trend of estimates for biomarker quintiles using 
their ordinal values with the contrast option in 
Proc Genmod. Models with continuous log-
biomarker variable were consistent with results 
of models using quintiles. We report results for 
pubertal stages assessed at visit 2, one year after 
urine collection, when the proportions with 
B2+ and PH2+ were greater and site variations 
were less pronounced. There were 985 girls with 
biomarkers and visit 2 breast stage and 967 with 
visit 2 pubic hair stages.
We hypothesized that exogenous expo-
sures were likely to operate jointly with BMI, 
a strong endogenous hormonal risk factor for 
pubertal development (Kaplowitz 2008). This 
hypothesis was examined by adding to models 
an interaction term for the product of the 
biomarker variable (log-continuous or ordinal 
quintile values) times BMI dichotomized at 
the median of the age-specific percentiles in 
our study population (low BMI/high BMI).
Results
BCERC cohort girls were 6–8 years of age 
and mainly black, Hispanic, and white race/
ethnicities (Table 1). Median ages differed by 
< 0.5 years across the sites, being youngest at 
MSSM and oldest at Cincinnati at both visits. 
Every site had > 20% blacks, but there were 
no whites from MSSM and very few Hispanics 
at Cincinnati. All characteristics including 
pubertal stages differed by site (Table 1; p 
< 0.01). Compared with normative national 
data for BMI, 65% of girls were above the 
50th percentile at visit 1 (i.e., 15% more than 
expected), 32% were above the 85th percen-
tile (overweight), and 17% were also above the 
95th percentile (obese) (CDC 2000). BMI% 
was highest among MSSM (median 75th 
percentile of the norm) and lowest among 
Cincinnati girls (median 64th percentile).
As expected, the environmental biomarkers 
were detected in almost all of the urine samples 
[Supplemental Material, Table 2 (doi:10.1289/
ehp.0901690)]. Overall, phenol median con-
centrations were < 100 µg/L, and urinary phy-
toestrogen and phthalate biomarker medians 
were > 400 µg/L. Geometric mean concentra-
tions (micrograms per liter) of urinary exposure 
biomarkers are presented in Table 2 mutually 
Table 2. Geometric means (95% CIs) of environmental urinary biomarkers at baseline examination in relation to covariates, mutually adjusted and for ln-urinary 
creatinine (1,102 girls with all characteristics, 2004–2007).
Phenols (µg/L) Phthalate monoesters, µg/L Phytoestrogens (µg/L)
BP3 BPA 2,5-DCP   Triclosan Paraben sum Low MWP High MWP   Daidzein   Genistein  Enterolactone
Age at baseline exam (years)
6.0–6.9 33 (24–45) 2.1 (1.8–2.4) 13 (10–17) 17 (13–23) 78 (61–101) 169 (145–199) 183 (158–212) 143 (106–194) 66 (49–90) 307 (248–381)
7.0–7.9 28 (21–37) 1.9 (1.7–2.2) 14 (11–18) 17 (13–23) 63 (50–79) 161 (140–186) 178 (156–202) 106 (81–139) 49 (37–64) 323 (267–390)
≥ 8.0 28 (20–38) 1.8 (1.5–2.1) 14 (11–19) 17 (13–23) 63 (48–81) 156 (133–182) 157 (136–182) 112 (83–151)* 50 (37–67)* 320 (259–396)
Race/ethnicity
White 51 (41–63) 2.0 (1.8–2.3) 6.0 (5.1–7.5) 14 (11–17) 39 (33–47) 114 (102–127) 179 (162–199) 118 (96–146) 56 (45–69) 396 (341–461)
Black 12 (10–15) 2.2 (2.0–2.4) 22 (18–26) 16 (13–19) 170 (143–201) 211 (190–233) 150 (137–165) 96 (79–116) 40 (33–49) 351 (306–403)
Hispanic, 
non-black
22 (17–27) 2.1 (1.9–2.3) 20 (17–24) 15 (12–19) 83 (69–99) 190 (170–212) 178 (160–197) 80 (65–98) 38 (31–47) 273 (235–318)
Asian 32 (20–52) 1.5 (1.2–2.0) 14 ( 9.0–21) 14 (9.1–23) 55 (37–82) 117 (91–149) 174 (139–219) 203 (127–324) 118 (74–188) 269 (193–375)
Other 52 (17–160)** 1.9 (1.1–3.3) 15 (5.5–38)** 32 (11–90) 46 (19–113)** 211 (120–369)** 182 (109–305)* 133 (46–384)** 47 (16–137)** 311 (146–663)**
BMI age-specific percentile at baseline
< 50th 31 (23–42) 2.0 (1.7–2.3) 13 (9.8–16) 19 (15–26) 70 (55–89) 153 (132–178) 180 (157–206) 116 (87–153) 53 (40–71) 376 (308–460)
50–85th 27 (20–36) 2.0 (1.7–2.3) 14 (11–18) 15 (12–20) 61 (48–78) 157 (136–182) 167 (146–192) 121 (91–161) 52 (39–69) 345 (282–421)
≥ 85th 31 (23–42) 1.9 (1.6–2.2) 15 (12–20) 17 (13–22) 72 (57–93) 177 (152–206) 170 (148–196) 121 (91–162) 58 (43–77) 245 (199–301)**
Caregiver education
12 years 24 (18–33) 1.9 (1.6–2.2) 15 (11–20) 18 (14–24) 63 (49–81) 174 (149–203) 178 (154–205) 117 (87–157) 55 (41–74) 288 (233–356)
≥ 13 years 36 (28–47)** 2 (1.7–2.3) 13 (10–17) 16 (13–21) 72 (58–90) 151 (132–173)* 167 (147–189) 122 (95–158) 54 (42–70) 347 (289–417)*
Study site
MSSM 22 (16–30) 2.3 (1.9–2.7) 46 (34–60) 15 (11–20) 70 (54–92) 201 (171–237) 242 (209–281) 89 (65–120) 42 (31–57) 287 (230–357)
Cincinnati 20 (14–28) 1.9 (1.6–2.2) 13 (9.6–17) 28 (21–39) 66 (50–88) 163 (138–194) 154 (131–180) 135 (97–186) 60 (43–82) 252 (200–318)
KPNC 58 (44–78)** 1.7 (1.5–2.0)** 4.7 (3.7–6.1)** 12 (9.0–16)** 66 (52–83) 129 (112–149)** 137 (120–157)** 143 (109–188)** 64 (49–84)* 439 (361–534)**
Season of urine collection
Spring 20 (15–27) 1.8 (1.5–2.0) 13 (10–17) 17 (13–22) 66 (51–84) 154 (132–179) 169 (147–194) 134 (101–178) 64 (48–85) 310 (253–380)
Summer 125 (92–172) 2.4 (2.1–2.8) 13 (10–17) 18 (14–24) 93 (72–121) 208 (177–243) 185 (160–214) 98 (73–132) 45 (33–60) 271 (219–335)
Fall 22 (16–30) 2.0 (1.7–2.4) 18 (14–24) 15 (11–21) 54 (41–70) 145 (123–171) 175 (151–204) 124 (91–170) 57 (42–77) 349 (280–436)
Winter 14 (10–19)** 1.6 (1.4–2.0)** 13 (9.9–18)* 18 (13–25) 63 (48–83)** 149 (126–176)** 161 (138–188) 125 (91–171) 55 (40–76)* 343 (273–430)
When any adjusted geometric mean differed from one or more of the others within a characteristic, the bottom value is marked with an asterisk. BMI% is sex- and age-specific (CDC 2000). 
Spring is March, April, May; other seasons follow sequentially. Paraben sum is the molar sum of methyl-, butyl-, and propyl-parabens, expressed as propylparaben (MW 180.2). Low MWP is the 
molar sum of MEP, MBP (monobutyl phthalate), MIBP expressed as MEP (MW = 194). High MWP is the molar sum of MBZP (mono-benzyl phthalate), MCPP [mono(3-carboxypropyl) phthalate], 
MEHP, MEOHP [mono-(2-ethyl-5-oxohexyl) phthalate], MEHHP [mono-(2-ethyl-5-hydroxyhexyl) phthalate], and MECPP [mono(2-ethyl-5-carboxypentyl) phthalate] expressed as MEHP (MW = 
278). DEHP metabolite sum, which was 75 ± 16% of high MWP and had almost identical means, is omitted from the table. Details are in Supplemental Material, Table 2 (doi:10.1289/ehp.0901690). 
*p < 0.05, **p < 0.01. Wolff et al.
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adjusted for covariates. Benzophenone-3 
(BP3), a sunscreen, was higher in samples col-
lected in the summer and among white chil-
dren, compared with blacks and Hispanics. 
2,5-Dichlorophenol (2,5-DCP) was lower in 
whites and higher in MSSM participants; it 
is the metabolite of 1,4-dichlorobenzene used 
in mothballs and room deodorizers. Parabens 
are found as preservatives in many personal 
care products; their levels were higher among 
blacks and in samples collected in summer. 
Parabens often occur together with BP3 
and low MWP in consumer products. Low-
MWP biomarkers were higher in blacks and 
Hispanics than whites and Asians. The isofla-
vones daidzein and genistein, which are found 
in soy products, were somewhat higher among 
Asians. Enterolactone, a gut metabolite of lig-
nans found in flax, beans, grains, and berries, 
tended to be higher among blacks and whites.
One year after urine samples were col-
lected for biomarker measurements, breast 
development was present in 30% and pubic 
hair in 22% of girls (Table 1). As shown in 
Table 3. PRs and 95% CIs for breast development stage (B2+ vs. B1) and pubic hair stage (PH2+ vs. PH1) in relation to urinary environmental biomarkers meas-
ured 1 year earlier. BCERC Cohort, 2004–2008.
Quintiles of creatinine-corrected biomarker concentrations (C)
1st 2nd 3rd 4th 5th p-Trend
Breast development
Phenols
BP3
Quintile median µg/gC 3.6 11.1 30.4 93.6 867
n B2+/n total 76/196 65/197 64/196 52/197 40/196
PR (95% CI) 1 (Ref) 0.96 (0.89–1.03) 0.96 (0.89–1.02) 0.91 (0.85–0.98) 0.87 (0.81–0.93) < 0.0001
Adj PR (95% CI) 1 (Ref) 1.00 (0.94–1.06) 1.01 (0.95–1.07) 0.99 (0.93–1.06) 1.01 (0.94–1.09) 0.847
BPA
Quintile median µg/gC 1.0 1.6 2.4 3.7 8.7
n B2+/total 69/196 59/197 54/196 61/197 54/196
PR (95% CI) 1 (Ref) 0.96 (0.90–1.03) 0.94 (0.88–1.01) 0.97 (0.90–1.04) 0.94 (0.88–1.01) 0.171
Adj PR (95% CI) 1 (Ref) 0.96 (0.90–1.02) 0.95 (0.89–1.01) 0.97 (0.91–1.03) 0.97 (0.91–1.03) 0.533
2,5-DCP
Quintile median µg/gC 1.6 4.0 10.7 37.2 179
n B2+/total 34/196 51/197 62/196 74/197 76/196
PR (95% CI) 1 (Ref) 1.07 (1.00–1.15) 1.12 (1.05–1.20) 1.17 (1.10–1.25) 1.18 (1.11–1.26) < .0001
Adj PR (95% CI) 1 (Ref) 0.99 (0.93–1.06) 0.97 (0.91–1.04) 1.04 (0.96–1.12) 1.02 (0.94–1.10) 0.416
Triclosan
Quintile median µg/gC 2.6 6.9 15 38 170
n B2+/total 57/196 49/197 59/196 65/197 67/196
PR (95% CI) 1 (Ref) 0.97 (0.90–1.04) 1.01 (0.94–1.08) 1.03 (0.96–1.10) 1.04 (0.97–1.11) 0.077
Adj PR (95% CI) 1 (Ref) 0.99 (0.93–1.05) 0.97 (0.92–1.03) 1.01 (0.95–1.07) 1.03 (0.97–1.10) 0.242
Paraben sum
Quintile median µg/gC 15 36 84 198 839
n B2+/total 45/180 50/181 58/181 45/181 68/180
PR (95% CI) 1 (Ref) 1.02 (0.95–1.10) 1.06 (0.98–1.14) 1.00 (0.93–1.07) 1.10 (1.03–1.18) 0.036
Adj PR (95% CI) 1 (Ref) 1.01 (0.95–1.07) 1.02 (0.96–1.09) 0.98 (0.92–1.04) 1.03 (0.96–1.10) 0.653
Phthalates
High MWP
Quintile median µg/gC 84 138 204 326 616
n B2+/total 67/196 62/197 53/196 40/197 75/196
PR (95% CI) 1 (Ref) 0.98 (0.91–1.05) 0.95 (0.88–1.02) 0.90 (0.84–0.96) 1.03 (0.96–1.10) 0.716
Adj PR (95% CI) 1 (Ref) 0.98 (0.92–1.04) 0.98 (0.92–1.04) 0.94 (0.88–1.00) 1.03 (0.97–1.10) 0.781
Low MWP
Quintile median µg/gC 66 112 173 272 721
n B2+/total 46/196 54/197 55/196 64/197 78/196
PR (95% CI) 1 (Ref) 1.03 (0.96–1.11) 1.04 (0.97–1.11) 1.07 (1.00–1.15) 1.13 (1.06–1.21) 0.000
Adj PR (95% CI) 1 (Ref) 1.03 (0.97–1.09) 1.01 (0.95–1.07) 1.04 (0.98–1.11) 1.06 (0.99–1.14) 0.087
Phytoestrogens
Daidzein
Quintile median µg/gC 20 48 104 281 1,359
n B2+/total 59/196 65/197 67/197 58/196 47/196
PR (95% CI) 1 (Ref) 1.02 (0.95–1.10) 1.03 (0.96–1.10) 1.00 (0.93–1.07) 0.95 (0.89–1.02) 0.121
Adj PR (95% CI) 1 (Ref) 1.05 (0.99–1.11) 1.02 (0.96–1.08) 1.00 (0.94–1.06) 0.96 (0.90–1.02) 0.061
Genistein
Quintile median µg/gC 9.4 20 45 127 610
n B2+/total 62/196 65/197 65/196 54/197 50/196
PR (95% CI) 1 (Ref) 1.01 (0.94–1.08) 1.01 (0.94–1.08) 0.97 (0.90–1.04) 0.95 (0.89–1.02) 0.081
Adj PR (95% CI) 1 (Ref) 1.02 (0.96–1.08) 1.00 (0.94–1.06) 0.97 (0.91–1.03) 0.97 (0.92–1.03) 0.103
Enterolactone
Quintile median µg/gC 97 283 522 899 1,922
n B2+/total 66/196 62/197 66/196 57/197 45/196
PR (95% CI) 1 (Ref) 0.98 (0.92–1.05) 1.00 (0.93–1.07) 0.96 (0.90–1.03) 0.92 (0.86–0.99) 0.018
Adj PR (95% CI) 1 (Ref) 1.02 (0.96–1.08) 1.03 (0.97–1.09) 1.00 (0.94–1.07) 1.03 (0.97–1.10) 0.462
continued next pageConcurrent environmental exposures and puberty in girls
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Table 3, the frequency of any breast and 
pubic hair development increased or decreased 
across quintiles of most biomarkers, but the 
adjusted PRs were close to null. Low MWP 
had weak positive associations with both 
breast and pubic hair stages. For breast devel-
opment, the adjusted PR was 1.06 (95% CI, 
0.99–1.14; p-trend = 0.087) in the fifth versus 
first quintile. The isoflavones daidzein and 
genistein had weak inverse associations with 
breast stage; for daidzein, the adjusted PR was 
0.96 for the fifth versus first quintile (95% 
CI, 0.90–1.02; p-trend = 0.061). Triclosan 
had a suggestive inverse association with 
pubic hair development, but the trend was 
not monotonic, and the CIs were similar for 
every quintile (Table 3). An inverse relation-
ship with pubic hair development was seen for 
high MWP.
Enterolactone modified the association of 
BMI with breast development. The propor-
tion of low-BMI girls at pubertal stages B2+ 
increased from 15 to 20% across enterolactone 
quintiles (see note to Table 4). Among girls 
Table 3 continued
Quintiles of creatinine-corrected biomarker concentrations (C)
1st 2nd 3rd 4th 5th p-Trend
Pubic hair development 
Phenols
BP3
Quintile median µg/gC 3.7 11 30 94 853
n PH2+/n total 48/195 54/195 40/191 35/194 33/189
PR (95% CI) 1 (Ref) 1.02 (0.96–1.10) 0.97 (0.91–1.04) 0.95 (0.89–1.01) 0.94 (0.88–1.01) 0.01
Adj PR (95% CI) 1 (Ref) 1.06 (1.00–1.14) 1.02 (0.96–1.09) 1.02 (0.95–1.09) 1.06 (0.98–1.15) 0.40
BPA
Quintile median µg/gC 1.0 1.6 2.4 3.8 8.8
n PH2+/total 39/194 44/196 52/190 38/191 37/193
PR (95% CI) 1 (Ref) 1.02 (0.95–1.09) 1.06 (0.99–1.14) 1.00 (0.93–1.07) 0.99 (0.93–1.06) 0.67
Adj PR (95% CI) 1 (Ref) 1.03 (0.96–1.09) 1.06 (0.99–1.13) 0.99 (0.92–1.05) 1.00 (0.94–1.07) 0.57
2,5-DCP
Quintile median µg/gC 1.6 4.0 11 37 179
n PH2+/total 32/189 32/192 40/195 57/194 49/194
PR (95% CI) 1 (Ref) 1.00 (0.94–1.06) 1.03 (0.97–1.10) 1.11 (1.03–1.18) 1.07 (1.00–1.15) 0.00
Adj PR (95% CI) 1 (Ref) 0.95 (0.89–1.02) 0.95 (0.89–1.02) 1.00 (0.92–1.08) 0.93 (0.86–1.01) 0.40
Triclosan
Quintile median µg/gC 2.6 6.9 15 38 170
n PH2+/total 56/191 37/192 44/192 32/195 41/194
PR (95% CI) 1 (Ref) 0.92 (0.86–0.99) 0.95 (0.89–1.02) 0.90 (0.84–0.96) 0.94 (0.87–1.00) 0.06
Adj PR (95% CI) 1 (Ref) 0.93 (0.87–0.99) 0.93 (0.87–0.99) 0.89 (0.83–0.94) 0.94 (0.88–1.00) 0.02
Paraben sum
Quintile median µg/gC 15 436 84 197 837
n PH2+/total 33/178 25/177 37/178 44/174 50/179
PR (95% CI) 1 (Ref) 0.96 (0.90–1.03) 1.02 (0.95–1.09) 1.06 (0.98–1.13) 1.08 (1.01–1.16) 0.00
Adj PR (95% CI) 1 (Ref) 0.94 (0.89–1.01) 0.95 (0.89–1.02) 1.02 (0.96–1.10) 0.97 (0.90–1.04) 0.80
Phthalates
High MWP
Quintile median µg/gC 84 138 203 327 613
n PH2+/total 55/193 44/195 37/191 35/192 39/193
PR (95% CI) 1 (Ref) 0.95 (0.89–1.02) 0.93 (0.87–0.99) 0.92 (0.86–0.98) 0.94 (0.87–1.00) 0.04
Adj PR (95% CI) 1 (Ref) 0.98 (0.92–1.04) 0.95 (0.90–1.01) 0.95 (0.89–1.01) 0.94 (0.88–1.00) 0.04
Low MWP
Quintile median µg/gC 66 112 173 272 718
n PH2+/total 30/190 30/192 50/194 44/195 56/193
PR (95% CI) 1 (Ref) 1.00 (0.94–1.06) 1.09 (1.02–1.16) 1.06 (0.99–1.13) 1.11 (1.04–1.19) 0.00
Adj PR (95% CI) 1 (Ref) 1.00 (0.94–1.06) 1.05 (0.98–1.12) 1.03 (0.97–1.10) 1.06 (0.98–1.13) 0.08
Phytoestrogens
Daidzein
Quintile median µg/gC 20 48 104 281 1,347
n PH2+/total 49/195 46/192 39/196 31/190 44/191
PR (95% CI) 1 (Ref) 0.99 (0.92–1.06) 0.96 (0.90–1.02) 0.93 (0.87–0.99) 0.98 (0.92–1.05) 0.18
Adj PR (95% CI) 1 (Ref) 1.01 (0.95–1.08) 0.97 (0.91–1.03) 0.95 (0.89–1.01) 1.00 (0.94–1.07) 0.39
Genistein
Quintile median µg/gC 9.5 20 46 129 607
n PH2+/total 48/193 45/194 45/193 26/194 45/190
PR (95% CI) 1 (Ref) 0.99 (0.92–1.06) 0.99 (0.92–1.06) 0.91 (0.85–0.97) 0.99 (0.92–1.06) 0.19
Adj PR (95% CI) 1 (Ref) 1.00 (0.94–1.06) 1.01 (0.95–1.07) 0.93 (0.88–0.99) 1.03 (0.96–1.09) 0.76
Enterolactone
Quintile median µg/gC 97 282 522 899 1,832
n PH2+/ total 45/195 37/193 48/194 40/195 39/187
PR (95% CI) 1 (Ref) 0.97 (0.91–1.04) 1.01 (0.95–1.09) 0.98 (0.92–1.05) 0.98 (0.92–1.05) 0.77
Adj PR (95% CI) 1 (Ref) 0.99 (0.93–1.05) 1.02 (0.96–1.08) 0.98 (0.92–1.05) 1.03 (0.96–1.10) 0.47
Abbreviations: Adj, adjusted; C, creatinine; Ref, referent. Adjusted models included age, race/ethnicity, sex- and age-specific BMI% (CDC 2000), guardian education, season of urine col-
lection, and site. There were fewer paraben measurements than other biomarkers because they were not measured early in the study. Quintile cut points were based on 982 girls with 
breast stage data, biomarkers, and creatinine. Quintile medians are among girls with breast or pubic stages. Breast stages were available for 981 girls with all biomarkers (963 for pubic 
hair); one additional girl with phthalate/  phenol biomarkers was B1, PH2+ (982 total breast, 964 PH); one additional girl with phytoestrogens was B2+, PH1 (982 total breast, 964 PH stages).Wolff et al.
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with high BMI, the proportion in the first 
quintile (48% B2+) decreased to 25% B2+ 
in the fifth quintile. This inverse association 
among high-BMI girls supported our hypoth-
esis, and it remained after further adjustment 
for covariates (Table 4). The difference in the 
enterolactone PRs between low- and high-
BMI groups suggests that higher entero  lactone 
exposures may attenuate the BMI association. 
Specifically, in the first quintile of enterolac-
tone in Table 4, the PR for pubertal stage B2+ 
versus B1 was 1.34 (95% CI, 1.23–1.45) for 
high BMI compared with low-BMI girls, the 
referent. This difference, the “BMI associa-
tion,” diminished steadily so that in the fifth 
quintile of enterolactone, the PRs for B2+ ver-
sus B1 were comparable for low BMI and high 
BMI (PR = 1.14 and 1.20, respectively, with 
similar CIs) (Table 4). Thus, breast develop-
ment differed among low- and high-BMI girls 
with low enterolactone exposure, but devel-
opment was similar at the highest exposure 
levels regardless of BMI. These enterolactone 
associations with breast stage were similar in 
models stratified by BMI and further adjusted 
for BMI%; results were also consistent by race/
ethnicity and by site.
Apparent modification by BMI% of three 
other biomarkers in relation to pubertal stages 
could be explained by residual confounding 
of race or BMI% [p-interactions < 0.1; see 
Supplemental Material, Table 3 (doi:10.1289/
ehp.0901690)]. In addition, genistein had a 
borderline interaction, but neither BMI stra-
tum exhibited a trend of the adjusted PRs 
across biomarker quintiles. 2,5-DCP exhib-
ited a positive association with breast develop-
ment among high-BMI girls (p-interaction = 
0.071; n = 948; p-trend 0.009), but in mod-
els stratified by BMI% further adjusted for 
BMI%, the association among high-BMI girls 
was null. The resulting attenuated estimate 
was similar to that of the main effect model 
for 2,5-DCP shown in Table 3. High MWP 
(p-interaction = 0.039) did not exhibit a dose–
response relationship with breast development 
in low- or high-BMI groups (p-trends > 0.80). 
BP3 exhibited patterns similar to those of 
enterolactone. The BP3 association with breast 
stage had a positive direction in low-BMI girls 
and an inverse relationship in high-BMI girls 
(p-interaction 0.088). However, no dose–
response relationship was evident. In BMI-
stratified models, among girls with low-BMI 
the adjusted PR was 1.08 for the fifth ver-
sus first quintile of BP3 (95% CI, 0.97–1.20; 
p-trend 0.15; n =4 69); in high-BMI girls the 
p-trend was 0.38 (not shown).
Discussion
In this group of 1,151 girls, we examined 
concurrent exposures from three chemical 
classes that possess known or likely hormonal 
activity in relation to pubertal development. 
Biologically relevant levels of the biomark-
ers existed among girls in the cohort. Most 
biomarkers were ubiquitously detected, and 
maximal concentrations were in the range 
known to elicit effects experimentally (e.g., 
> 10 µmol). Overall, biomarker concentrations 
were similar to those reported in the National 
Health and Nutrition Examination Survey 
(NHANES) for children 6–11 years of age 
(CDC 2005), as were those in the pilot study 
(Wolff et al. 2007). These urinary metabo-
lites are derived from common personal and 
household products or dietary sources, and 
absorption may occur through ingestion, inha-
lation, or dermal routes (National Science 
Foundation 2008).
Associations of concurrent exposure bio-
markers with breast and pubic hair develop-
ment in these girls were not strong, but those 
observed were among the chemicals with 
greatest exposure levels. The strongest finding 
was attenuation by enterolactone exposure 
of the BMI association with breast develop-
ment. Along with the inverse relationships of 
daidzein and genistein with breast develop-
ment and high MWP with pubic hair stage, 
the results were consistent with our a priori 
hypotheses and the experimental literature. 
Comparable associations of phytoestrogens 
with breast stage were seen in an earlier small 
study (Wolff et al. 2008). Phytoestrogens 
including enterolactone are known to pos-
sess hormonal activity (Adlercreutz 2002). A 
protective effect for puberty might be con-
sistent with counteracting the influence of 
obesity (Horn-Ross 1995) or by reducing 
adiposity (Cederroth et al. 2007). In con-
trast, associations were positive, albeit very 
weak, for low MWP with both breast and 
hair development. It is not clear why low- and 
high-MWP metabolites could have opposite 
associations with developmental stages, yet 
various reports of such exposures in humans 
and animals show divergent hormonal asso-
ciations, depending on timing and inten-
sity of exposure or treatment and on rodent 
strain (Adlercreutz 2002; Rasier et al. 2006; 
Schoeters et al. 2008; Shen et al. 2009). In 
addition, patterns and density of ambient 
exposures no doubt differ for the low MWPs 
and high MWPs (Adibi et al. 2008).
Residual confounding or misclassification 
of exposures and outcomes remain possible 
explanations for our results. Collinearity of 
covariates, such as that among BMI, race/
ethnicity, urinary creatinine, and urinary bio-
markers and their variation by study site, are 
potential difficulties. We used methods with 
robust variance handling in an effort to mini-
mize such problems. A potential explanation 
for the lack of strong associations is overad-
justment of the models due to the inclusion 
of certain covariates (Greenland et al. 1999; 
Weinberg 1993). For example, BMI may 
be both a confounder and on the pathway 
between exposure and pubertal development. 
Considering the interrelationships among our 
variables, the models presented are the most 
appropriate. For our main analyses, we used 
creatinine-corrected biomarker concentrations 
to create quintile cut points. Creatinine cor-
rection may be inadequate for some or all 
analytes. However, we did not measure spe-
cific gravity, an alternate measure of urine 
dilution (Hauser et al. 2004; Miller et al. 
2004). Other methods, such as the regres-
sion normalization procedures (Heavner et al. 
2006), may not be appropriate for all urinary 
metabolites. Besides exposure misclassifica-
tion, there is potential error in the outcome 
measurement of pubertal stage because of 
inter-rater variability in pubertal stage assess-
ment. Therefore, both exposure and outcome 
measurements may be subject to nondifferen-
tial misclassification bias, which would likely 
shift the estimates toward the null. Additional 
considerations, including genetic and racial 
differences in exposure and development, 
would require considerably larger sample size. 
Table 4. Adjusted PRs (95% CIs) for any breast development stage (B2+ vs. B1) at visit 2 in relation to urinary environmental biomarkers and age-specific BMI 
measured at visit 1.
Urinary enterolactone quintile [median creatinine (C) corrected biomarker concentration (µg/gC) for quintile]
1st (97 µg/gC) 2nd (283 µg/gC) 3rd (522 µg/gC) 4th (899 µg/gC) 5th (1,922 µg/gC) p-Trend
n B2+ / n total 12/84 14/82 17/99 20/102 27/124
Adjusted PR (95% CI) among low-BMI girls  
(BMI% range, < 1 to 68%; median = 36.0%)
1.0 (ref) 1.06 (0.96–1.15) 1.05 (0.96–1.15) 1.11 (1.01–1.22) 1.15 (1.05–1.26) 0.0016
n B2+ / n total  54/11      2 48/115 49/97 37/95 18/72
Adjusted PR (95% CI) among high-BMI girls  
(BMI% range, 68.5 to > 99%; median = 90.1%)
1.34 (1.23–1.45) 1.30 (1.20–1.42) 1.35 (1.24–1.48) 1.24 (1.13–1.36) 1.21 (1.10–1.33) 0.0105
PRs were computed from model with interaction term (ordinal values of enterolactone biomarker quintiles times 2-level BMI), adjusted for age at visit 2, race/ethnicity, site, caregiver 
education, season of urine c                ollection. p-Interaction = 0.0006.Concurrent environmental exposures and puberty in girls
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We estimated that for the main effects we had 
adequate power (80%) to detect PRs of 1.1 in 
479 girls, if B2+ or PH2+ were > 20% in the 
fifth quintile (alpha 0.05), and a PR of 0.94 
with 948 girls; these values are similar to the 
strongest associations we observed. Our effect 
estimates also may be conservative, because we 
used Poisson models instead of logistic regres-
sion models. For example, for the PR of 0.94 
(95% CI, 0.88–1.00, high MWP and PH2+) 
in Table 3, we computed an odds ratio (OR) 
of 0.60 (95% CI, 0.34–1.06). However, mea-
sures of association using ORs may be over- 
or underestimated (Zou 2004). Finally, some 
or all of our findings may be due to chance; 
> 100 comparisons were made for the mod-
els presented in Tables 3 and 4. Associations 
of hormonal exposures in this study were 
small, which may be consistent with their 
relatively weak biological activity compared 
with endogenous hormones (Fang et al. 2000; 
Shen et al. 2009). Small effect estimates may 
be more realistic than those in previous stud-
ies that had small sample sizes (Wolff et al. 
2008). There will be greater power to detect 
associations in longitudinal analyses that can 
also better reflect causal relationships than 
cross-sectional analyses; we plan to under-
take such analyses as the cohort matures. The 
reports of delayed pubertal development in 
relation to blood lead concentrations in the 
NHANES population are informative for our 
findings, as the lead effects appear stronger 
than those we observed. Selevan et al. (2003)
observed among black girls an OR of 0.62 
(95% CI, 0.41–0.96, multivariate adjusted) 
for PH2+ versus PH1 among girls with blood 
lead > 3 µg/dL, quartile of exposure, com-
pared with those having blood lead < 1 µg/dL, 
approximately the upper versus first quartile 
of their exposures. For the same NHANES 
population, Wu et al. (2003) found ORs for 
PH2+ of 0.27 (95% CI, 0.08–0.93) in the 
top exposure group (≥ 5 µg/dL) compared 
with ≤ 2 µg/dL blood lead. The proportion of 
PH2+ in the low exposure stratum was 81% 
versus 44% at high exposure. By comparison, 
the prevalence of PH2+ was 28% in the first 
compared with 20% in the fifth quintile of 
high MWP in Table 3, and the adjusted PR 
was 0.94 (95% CI, 0.88–1.00). High-MWP 
medians were 7-fold different between these 
quintiles compared with 3-fold differences in 
the lead exposure categories.
An additional consideration is that the 
peripubertal period is likely not the only criti-
cal window of exposure for pubertal develop-
ment. Both animal and epidemiology studies 
suggest that prenatal and perinatal exposures 
also exert effects on later development (Rasier 
et al. 2006; Schoeters et al. 2008). Exposures 
during different windows may affect different 
molecular targets, including prenatal imprint-
ing, the hypothalamic-pituitary axis, gonado-
tropin-releasing hormone neurons, hormone 
receptors, and aromatase action (Schoeters 
et al. 2008). Effective exposure ranges for 
these mechanisms may also differ widely, that 
is, toxic equivalents. Environmental agents 
in our study are cleared rapidly; it is possible 
that a single biomarker measurement is inade-
quate to quantify exposure relevant to pubertal 
development. However, single measurements 
of urinary biomarkers of phenols and phtha-
lates were fairly representative of 6–12 months 
of exposure in children this age (Teitelbaum 
et al. 2008), likely because of common use 
and continuous exposure to many chemicals. 
Time-integrated multiple childhood exposure 
measures prenatally and prepubertally may be 
possible in alternate study designs. An impor-
tant additional direction is to evaluate multiple 
exposures, including the extremes of exposure, 
multiple high exposures, early life exposures, 
and/or extremes of development (very late vs. 
very early changes) (Chou et al. 2009).
As we have mentioned, these environmen-
tal biomarkers were considered important for 
pubertal development because their concen-
trations are higher and in some cases their 
bioassay potency is greater than commonly 
studied environmental agents such as lead and 
1,1´-dichloro-2,2´-bis(4-chlorophenyl)ethyl-
ene (DDE). Although the suggestive associa-
tions we observed are small, within 10% of 
null, a small effect size could affect a signifi-
cant proportion of the population because of 
the ubiquity of these exposures and by their 
high levels (micromolar) observed in urine of 
the BCERC cohort.
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